Zoetis Inc. (ZTS) Receives Consensus Recommendation of “Buy” from Brokerages
Shares of Zoetis Inc. (NYSE:ZTS) have been assigned an average recommendation of “Buy” from the eighteen research firms that are currently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and twelve have issued a buy rating on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $65.76.
A number of brokerages recently commented on ZTS. Cowen and Company set a $60.00 price target on Zoetis and gave the stock a “buy” rating in a research note on Tuesday, July 11th. Cantor Fitzgerald set a $75.00 price target on Zoetis and gave the stock a “buy” rating in a research note on Monday, August 14th. Zacks Investment Research raised Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price target for the company in a research note on Thursday. Stifel Nicolaus reaffirmed a “buy” rating and issued a $65.00 price target on shares of Zoetis in a research note on Friday, July 21st. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and issued a $62.00 price target on shares of Zoetis in a research note on Monday, August 7th.
Shares of Zoetis (NYSE ZTS) traded up 0.98% on Thursday, hitting $64.91. 1,837,949 shares of the stock were exchanged. Zoetis has a 52-week low of $46.86 and a 52-week high of $65.83. The company has a market cap of $31.75 billion, a price-to-earnings ratio of 36.69 and a beta of 1.02. The company has a 50 day moving average of $63.65 and a 200 day moving average of $60.76.
Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 8th. The company reported $0.53 EPS for the quarter, hitting analysts’ consensus estimates of $0.53. Zoetis had a return on equity of 62.49% and a net margin of 17.50%. The company had revenue of $1.27 billion during the quarter, compared to analyst estimates of $1.27 billion. During the same quarter last year, the firm posted $0.49 earnings per share. The firm’s revenue was up 5.0% on a year-over-year basis. Equities research analysts forecast that Zoetis will post $2.34 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Thursday, November 9th will be given a dividend of $0.105 per share. This represents a $0.42 annualized dividend and a yield of 0.65%. The ex-dividend date is Wednesday, November 8th. Zoetis’s dividend payout ratio is currently 23.73%.
Institutional investors have recently made changes to their positions in the business. Northwestern Mutual Wealth Management Co. lifted its position in Zoetis by 16.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock valued at $100,000 after buying an additional 230 shares during the period. Guardian Life Insurance Co. of America increased its holdings in shares of Zoetis by 0.7% during the first quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock valued at $102,000 after acquiring an additional 13 shares in the last quarter. Point72 Asia Hong Kong Ltd bought a new position in shares of Zoetis during the first quarter valued at $111,000. Harfst & Associates Inc. increased its holdings in shares of Zoetis by 16.1% during the second quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock valued at $117,000 after acquiring an additional 260 shares in the last quarter. Finally, Almanack Investment Partners LLC. bought a new position in shares of Zoetis during the second quarter valued at $119,000. 93.20% of the stock is owned by institutional investors and hedge funds.
WARNING: “Zoetis Inc. (ZTS) Receives Consensus Recommendation of “Buy” from Brokerages” was originally published by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.americanbankingnews.com/2017/10/12/zoetis-inc-zts-receives-consensus-recommendation-of-buy-from-brokerages.html.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.